What You Should Know:
– GE HealthCare, a leader in ultrasound-guided urology solutions, has announced the launch of Prostate Volume Assist (PVA).
– The AI-powered solution is designed to empower urologists with faster and more efficient…
Continue Reading
Avenda Health’s groundbreaking Unfold AI platform represents a monumental advancement in prostate cancer management, enabling unparalleled precision and personalized treatment strategies. Through sophisticated AI algorithms, Unfold AI integrates patient-specific data to generate comprehensive cancer…
Continue Reading
What You Should Know:
ArteraAI, a leader in artificial intelligence (AI)-powered cancer tests, today announced a significant achievement – the inclusion of their ArteraAI Prostate Test in the NCCN Clinical Practice Guidelines in Oncology (NCCN…
Continue Reading
Background: Androgen deprivation therapy (ADT), a standard treatment for prostate cancer (PC), causes many physical side effects. In particular, it causes metabolic changes such as fasting glucose abnormalities or accumulation of body fat, and…
Continue Reading
GE HealthCare announced a collaboration with Grand Rapids-based cancer treatment center BAMF Health to advance the adoption of theranostics in the U.S. Theranostics is an emerging technology and a form of precision medicine that fuses…
Continue Reading
Dr. Robert Bard, a leader in radiological diagnostics, advocates for 3D Doppler imaging’s role in non-invasive cancer detection, particularly in breast, prostate, and skin cancers. Highlighting its precision and the reduced need for biopsies,…
Continue Reading
Avenda Health’s AI tool, Unfold AI, for mapping prostate cancer, received a Category III CPT code for 2024 from the AMA. The code, X237T, facilitates precise cancer localization and treatment planning through an AI-generated…
Continue Reading
Philips and Quibim have teamed up to develop AI-enhanced MR imaging and reporting solutions for prostate exams. This partnership aims to improve prostate cancer care efficiency and accuracy, providing an alternative to traditional PSA…
Continue Reading
A Corewell Health study suggests that men with longer prostatic urethras face a higher risk of urinary side effects after prostate cancer radiation therapy. By utilizing a novel MRI metric, researchers found that for…
Continue Reading
Blue Earth Diagnostics, a leading provider of PET radiopharmaceuticals, is set to present findings on POSLUMA (flotufolastat F 18) injection at the ASTRO 2023 Annual Meeting. POSLUMA aids in PET scans to detect prostate-specific…
Continue Reading
